The median time to worsening performance status ( a change in Eastern Cooperative Oncology Group performance status [ on a scale of 0 to 5 , with 0 indicating no symptoms and higher numbers indicating increasing degrees of disability ] from 0 or 1 to 2 or more ) was 5.7 months with TAS-102 versus 4.0 months with placebo ( hazard ratio , 0.66 ; 95 % CI , 0.56 to 0.78 ; P < 0.001 ) .